Adagio Therapeutics Inc

-0.65 (-1.40%)
4:04:44 PM EDT: $45.18 -0.66 (-1.44%)
Regulatory, Earnings Announcements

Adagio Therapeutics Provides Update For Adg20 Covid-19 Antibody Program, Reports Q3 results

Published: 11/15/2021 12:03 GMT
Adagio Therapeutics Inc (ADGI) - Adagio Therapeutics Provides Update for Adg20 Covid-19 Antibody Program and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.98.
FDA Feedback Supports Planned Emergency Use Authorization (eua) Submission for Adg20 for Prevention of Covid-19.
Adagio Therapeutics - Interim Clinical Data Package From Evade Prevention Trial to Support Eua Submission Expected in Q2 2022.
Q3 Earnings per Share View $-0.74 -- Refinitiv Ibes Data (analyst estimates).
Cash, Cash Equivalents and Marketable Securities Expected to Support Company's Current Operating Plans Into 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.03

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.07

More details on our Analysts Page.